Phase II Trial of Taletrectinib in Chinese Patients with ROS1+ NSCLC
| Title | Phase II Trial of Taletrectinib in Chinese Patients with ROS1+ NSCLC |
|---|---|
| Description | The purpose of the study is to evaluate safety, pharmacokinetics and efficacy of AB-106 monotherapy in the treatment of advanced NSCLC |
| Organism | Homo sapiens |
| Data Type | Genetic Biomarkers |
| Data Accessibility | Controlled-access |
| BioProject | PRJCA023373 |
| Release Date | 2024-03-18 |
| Submitter | ling zhang (shfkgcp@163.com) |
| Organization | shanghai pulmonary hospital |
| Submission Date | 2024-02-01 |
The data cannot be downloaded as it has not yet been registered in the Human Genetic Resource Management Platform of MOST.
| File ID | File Title | Number/Samples | File Type | File Size | File Suffix | Download Times | Download |
|---|---|---|---|---|---|---|---|
| OMIX005787-01 | AB-106-C203_ctDNA_test_Mutation_Summary | 290 | Genetic Biomarkers | 119.9 KB | xlsx | 0 | Unavailable |
| OMIX005787-02 | AB-106-C203_ctDNA_test_ROS1_Result | 290 | Genetic Biomarkers | 48.0 KB | xlsx | 0 | Unavailable |
| OMIX005787-03 | AB-106-C203_local_test_ROS1_Result | 173 | Genetic Biomarkers | 16.0 KB | xlsx | 0 | Unavailable |
| OMIX005787-04 | AB-106-C203_tissue_test_ROS1_Result | 262 | Genetic Biomarkers | 56.3 KB | csv | 0 | Unavailable |